Neoprobe Corp. underwrote a public offering of 2 million shares ofcommon stock at $2.27 per share, raising $4.54 million for theDublin, Ohio, company.The shares were sold by Neoprobe to institutional investors. Thecompany will have 10.9 million shares outstanding, and will havecash to last through September 1995, David Bupp, Neoprobe'spresident, told BioWorld. Neoprobe had $3.4 million in cash as ofJune 30.The company is developing radioimmunoguided surgery (RIGS)products, to detect and characterize various cancers. It has RIGSproducts in Phase II testing for ovarian and breast cancers, a PhaseIII trial in metastatic colorectal cancer and three therapeuticproducts in early clinical testing. _ Jim Shrine

(c) 1997 American Health Consultants. All rights reserved.